Currently, products on the market have used Fruitflow in its syrup form.
UK firm Provexis says that focus is now fixed on developing a powder version of Fruitflow, a tomato-based ingredient Provexis developed that helps maintain healthy platelet aggregation and improve blood flow. Provexis says that a powder version would allow the ingredient to be formulated for tablet- and capsule-form dietary supplements. Currently, products on the market have used Fruitflow in its syrup form.
The company says the decision to develop Fruitflow powder stems from strong commercial interest from the supplements sector. DSM Nutritional Products (Parsippany, NJ), which currently licenses the Fruitflow trademark, is said to be currently developing tablet and capsule powder formats.
At the end of last year, Provexis says that a small-scale production run of Fruitflow powder was tested for bioavailability by Provexis’s lab at the University of Aberdeen. Moreover, in January of this year, an industrial-scale production of the powder was successfully completed.
In other news, Provexis says that it has identified a potential application for Fruitflow in the sports nutrition market and has developed a product that will launch in the UK this summer.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.